They demonstrated that elevated Mapk14-Atf2 signaling is a poor prognostic factor in sorafenib therapy of human HCC, which may translate to a promising novel approach to identify HCC patients with sorafenib resistance. Here, MAPK14 is linked to hepatocellular carcinoma.